Pallas Capital Advisors LLC Purchases 75 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Pallas Capital Advisors LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,461 shares of the pharmaceutical company’s stock after acquiring an additional 75 shares during the period. Pallas Capital Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $991,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. GHP Investment Advisors Inc. purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter worth approximately $29,000. HBK Sorce Advisory LLC bought a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $240,000. Envestnet Asset Management Inc. lifted its stake in Vertex Pharmaceuticals by 2.9% in the second quarter. Envestnet Asset Management Inc. now owns 415,060 shares of the pharmaceutical company’s stock worth $194,547,000 after acquiring an additional 11,751 shares during the period. J.W. Cole Advisors Inc. increased its position in Vertex Pharmaceuticals by 8.1% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 845 shares of the pharmaceutical company’s stock valued at $396,000 after purchasing an additional 63 shares during the period. Finally, Brown Brothers Harriman & Co. raised its holdings in Vertex Pharmaceuticals by 4.3% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 2,504 shares of the pharmaceutical company’s stock worth $1,174,000 after purchasing an additional 104 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Up 0.9 %

NASDAQ:VRTX opened at $413.37 on Tuesday. The company has a market cap of $106.45 billion, a PE ratio of -207.72 and a beta of 0.40. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $447.69 and a two-hundred day simple moving average of $467.53. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Vertex Pharmaceuticals’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.67 earnings per share. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. Canaccord Genuity Group increased their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. Jefferies Financial Group upgraded Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the company from $500.00 to $550.00 in a research report on Monday, December 9th. Oppenheimer downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Finally, HC Wainwright reduced their target price on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a research report on Friday, December 20th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.